{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:15:47Z","timestamp":1793164547033,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semarthrit.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T06:58:55Z","timestamp":1519196335000},"page":"149-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study"],"prefix":"10.1016","volume":"48","author":[{"given":"G.","family":"Boleto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wipff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Forien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dieude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.02.010_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","article-title":"New drugs for aggressive B-cell and T-cell lymphomas","volume":"11","author":"Murawski","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2016.09.011","article-title":"Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients\u2014a longitudinal analysis","volume":"46","author":"Wunderlich","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semarthrit.2012.12.024","article-title":"Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis","volume":"43","author":"Johnston","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib9","unstructured":"Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [Internet]. ACR Meeting Abstracts. [cited 2017 Oct 6]. Available from: http:\/\/acrabstracts.org\/abstract\/long-term-risk-of-serious-infections-in-patients-with-rheumatoid-arthritis-treated-with-rituximab-5-year-data-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis\/"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib10","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jbspin.2011.12.004","article-title":"Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections","volume":"79","author":"Isvy","year":"2012","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.semarthrit.2018.02.010_bib17","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","article-title":"Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0","volume":"34","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib23","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/art.38736","article-title":"Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic","volume":"66","author":"Glaesener","year":"2014","journal-title":"Arthritis Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/gastro\/gou082","article-title":"Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease","volume":"3","author":"Rai","year":"2015","journal-title":"Gastroenterol Rep"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib25","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.semarthrit.2016.10.007","article-title":"Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years","volume":"46","author":"Avouac","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.med.48.1.93","article-title":"Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency","volume":"48","author":"Lee","year":"1997","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib29","first-page":"893","article-title":"Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study","volume":"34","author":"Vassilopoulos","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib30","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients","volume":"16","author":"Wendler","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2249.2002.02004.x","article-title":"Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study","volume":"130","author":"Mellemkjaer","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.02.010_bib35","first-page":"CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:34:42Z","timestamp":1541464482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217307370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0049017217307370"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}